TY - JOUR
T1 - New insights into the location and form of sclerostin
AU - Hernandez, Paula
AU - Whitty, Ciara
AU - John Wardale, R.
AU - Henson, Frances M.D.
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2014/4/18
Y1 - 2014/4/18
N2 - Sclerostin is widely reported to be a monomeric osteocyte specific protein. In this study we have investigated whether sclerostin is produced in different forms and in which cell and tissue types they are produced. We have demonstrated that recombinant sclerostin is composed of monomers and dimers, and that these, and other forms, notably 46 and 70 kDa forms, are found widely throughout the musculo-skeletal system. We have shown that 'dimeric' sclerostin is highly resistant to reduction, implying the presence of highly stable, non-reducible covalent bonds. We have also demonstrated that the form of sclerostin is not associated with the mineralisation state of the tissue or cell. Sclerostin was secreted by bone explants as high molecular weight forms that were reducible to the dimeric form. This dimeric form was detected in sera and in non-skeletal soft tissues specifically kidney, live, heart and lung. We therefore hypothesise: (a) sclerostin exists in multiple forms not associated with the mineralised state of the cell/tissue and (b) circulating sclerostin is dimeric, as is the sclerostin found in non-musculoskeletal soft tissues these observations may have significant implications for the therapeutic modulation of sclerostin.
AB - Sclerostin is widely reported to be a monomeric osteocyte specific protein. In this study we have investigated whether sclerostin is produced in different forms and in which cell and tissue types they are produced. We have demonstrated that recombinant sclerostin is composed of monomers and dimers, and that these, and other forms, notably 46 and 70 kDa forms, are found widely throughout the musculo-skeletal system. We have shown that 'dimeric' sclerostin is highly resistant to reduction, implying the presence of highly stable, non-reducible covalent bonds. We have also demonstrated that the form of sclerostin is not associated with the mineralisation state of the tissue or cell. Sclerostin was secreted by bone explants as high molecular weight forms that were reducible to the dimeric form. This dimeric form was detected in sera and in non-skeletal soft tissues specifically kidney, live, heart and lung. We therefore hypothesise: (a) sclerostin exists in multiple forms not associated with the mineralised state of the cell/tissue and (b) circulating sclerostin is dimeric, as is the sclerostin found in non-musculoskeletal soft tissues these observations may have significant implications for the therapeutic modulation of sclerostin.
KW - Bone
KW - Cartilage
KW - Sclerostin
KW - Wnt
UR - http://www.scopus.com/inward/record.url?scp=84899472921&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899472921&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2014.03.079
DO - 10.1016/j.bbrc.2014.03.079
M3 - Article
C2 - 24667598
AN - SCOPUS:84899472921
VL - 446
SP - 1108
EP - 1113
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
SN - 0006-291X
IS - 4
ER -